Last reviewed · How we verify
NCT05964036
pBFS-guided High-dose TMS Over DMPFC for Treatment-resistant Major Depressive Disorder
NA trial testing active TMS in Depression in 45 participants. Status unknown.
20 April 2024
Quick facts
| Lead sponsor | Changping Laboratory |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 45 |
| Start date | 21 July 2023 |
| Primary completion | 20 April 2024 |
| Estimated completion | 20 July 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- active TMS
- sham TMS
Conditions studied
- Depression — all drugs for Depression →
- Major Depressive Disorder — all drugs for Major Depressive Disorder →
- Severe Depression — all drugs for Severe Depression →
Sponsor
Changping Laboratory
Who can join
Adults 18 to 65, any sex, with Depression or Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators aim to evaluate the safety and efficacy of pBFS-guided DMPFC target and high-dose rTMS therapy for the treatment of patients with treatment-resistant depression
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05964036
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of active TMS
Trials testing the same drug.
- NCT07293780 — Effect of TMS on Neuropathic Pain for Patients With Sci · NA · recruiting
- NCT06570824 — rTMS as an Intervention for Levodopa-induced Dyskinesia · NA · recruiting
- NCT03994991 — Transcranial Magnetic Stimulation (TMS) for Thoracic Surgery · NA · withdrawn
- NCT04586205 — Task Augmentation of Transcranial Magnetic Stimulation (TMS) · completed
Other recruiting trials for Depression
Currently open trials in the same condition.
- NCT07336238 — Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or · Phase 2 · recruiting
- NCT06906939 — A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression · EARLY_PHASE1 · recruiting
- NCT07517549 — Sexual Health Education During Pregnancy · NA · recruiting
- NCT06408246 — ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression · Phase 2 · recruiting
- NCT07449676 — Effects of an Innovative TCM-based Tui Jing Therapy on Psychological and Neurophysiological Functions in Depression · NA · recruiting
Other Changping Laboratory trials
Trials by the same sponsor.
- NCT06350396 — pBFS-guided rTMS Over DMPFC for Treatment-Resistant Depression · NA · recruiting
- NCT06255535 — pBFS Guided rTMS Over Cognitive Control Network for ASD · NA · recruiting
- NCT06255561 — pBFS Guided rTMS Over Different Targets for Treatment-Resistant Depression · NA · unknown
- NCT06166082 — Stanford Neuromodulation Therapy (SNT) for the Treatment-Resistant Depression · NA · unknown
- NCT06112652 — Neuromodulation of Different Doses to Treat TRD Guided by pBFS Technique · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05964036 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Changping Laboratory
- Last refreshed: 7 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05964036.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing